Mononucleosis Diagnostic Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Mononucleosis, primarily caused by the Epstein-Barr virus, requires laboratory confirmation through serological and molecular testing methods. The global market for these diagnostic solutions is currently valued at approximately $2.0 billion, with projections indicating continued expansion toward $2.8 to $3.2 billion by 2030 to 2032. Growth rates across multiple industry analyses cluster consistently around 4.6% to 4.8% annually over the near term.

• •Market valued at approximately $2.0 billion as of recent estimates
• •Projected to reach $2.8 to $3.2 billion by 2030 to 2032
• •Annual growth rates cluster around 4.6% to 4.8% over the near term

Increasing prevalence of infectious mononucleosis, particularly among adolescents and young adults, continues to drive sustained diagnostic demand globally. Advances in point-of-care testing and molecular diagnostics are expanding testing accessibility beyond traditional centralized laboratory settings. Growing healthcare infrastructure investment and diagnostic awareness in emerging markets further support long-term market expansion.

• •Rising EBV infection rates in adolescent and young adult populations
• •Adoption of rapid point-of-care and molecular diagnostic platforms
• •Expansion of healthcare access and diagnostic testing in developing regions

North America and Europe historically dominate the market due to established healthcare infrastructure, high diagnostic awareness, and widespread insurance coverage for infectious disease testing. Asia-Pacific is emerging as the fastest-growing regional market, driven by rising healthcare expenditure, improving laboratory networks, and growing awareness of EBV diagnostics. The technology segment includes serological assays, molecular tests, and rapid immunoassays, with molecular diagnostics representing the fastest-growing category.

• •North America and Europe hold the largest market shares
• •Asia-Pacific is the fastest-growing regional market
• •Molecular diagnostics is the fastest-growing technology segment

Who are the notable companies in the industry?

The mononucleosis diagnostic market exhibits moderate fragmentation, with a mix of large integrated diagnostics manufacturers and specialty infectious disease testing firms operating across the value chain. Among the established players, Roche represents a major integrated diagnostics manufacturer; in April 2021, the company launched its Elecsys EBV panel, comprising Elecsys EBV IgM, Elecsys EBV VCA IgG, and Elecsys EBV EBNA IgG immunoassays, across countries accepting the CE Mark, reinforcing its position in immunoassay-based EBV detection. Quanterix Corporation, meanwhile, operates as a specialty infectious disease testing firm leveraging digital immunoassay platforms; in January 2022, the company reported that its Simoa technology demonstrated significance in identifying a high prevalence of EBV associated with multiple sclerosis, underscoring its role in advancing serological detection with enhanced sensitivity. Production across the sector relies primarily on immunoassay and molecular amplification technologies, with supply chains and manufacturing capacity concentrated in North America, Europe, and East Asia. Capacity is distributed across multinational diagnostic corporations and regional contract manufacturers, with ongoing industry consolidation as larger players seek to acquire specialized testing capabilities and expand geographic reach.

• •Moderate fragmentation between integrated diagnostics manufacturers and specialty producers
• •Primary technology routes include immunoassay and molecular amplification platforms
• •Production capacity concentrated in North America, Europe, and East Asia

What are the recent trends and outlook?

The shift toward decentralized testing and molecular diagnostics is reshaping product development priorities and go-to-market strategies across the industry. Integration of artificial intelligence in result interpretation, workflow automation, and laboratory information systems is becoming increasingly prevalent in developed markets. Over the forecast period, the market is expected to maintain steady growth as EBV testing becomes increasingly integrated into broader infectious disease screening panels and point-of-care settings expand globally.

• •Growing adoption of decentralized and molecular testing platforms
• •Increasing integration of AI and automation in diagnostic workflows
• •EBV testing becoming standard in broader infectious disease screening panels